Omeros (NASDAQ:OMER) Upgraded at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a report issued on Tuesday.

Separately, Needham & Company LLC reaffirmed a hold rating on shares of Omeros in a research report on Tuesday, June 4th.

Omeros Trading Down 6.9 %

OMER stock opened at $5.02 on Tuesday. The company has a 50 day moving average of $4.22 and a two-hundred day moving average of $3.87. Omeros has a 12-month low of $0.92 and a 12-month high of $5.68.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.13). Equities research analysts expect that Omeros will post -1.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Omeros

Several institutional investors have recently bought and sold shares of the stock. Comerica Bank increased its holdings in shares of Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 5,000 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Omeros by 199.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,069 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 5,378 shares during the period. Rhumbline Advisers lifted its stake in shares of Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after buying an additional 6,435 shares during the last quarter. Coldstream Capital Management Inc. boosted its holdings in shares of Omeros by 42.1% during the 4th quarter. Coldstream Capital Management Inc. now owns 28,130 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 8,335 shares during the period. Finally, Cypress Capital Group grew its stake in Omeros by 40.0% in the 2nd quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 10,000 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.